RNAC Company Profile and Key Details

RNAC has shown mixed momentum, losing -0.55% over the past week and -19.76% over the past quarter, though year-to-date performance is up 0.28%. Short-term trend indicators are bullishly aligned (SMA20 21.62%, SMA50 16.52%, SMA200 -9.8%). The stock’s 14-day RSI is 71.57 (overbought), while the ATR of 0.55 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -57.05% below its high and over 39.63% above its low. Average 10-day trading volume of 122.81 thousand shares is below the 3-month average of 280.76 thousand, indicating normal recent market interest.

Cartesian Therapeutics, Inc. has 29.38 million shares outstanding. The public float is 10.63 million shares, elevated short interest at 14.81% of float. This equals 1.93 million shares. The short ratio is 7.04 days. Institutional investors hold 54.37% of the float. Insiders own 53.68%. SPRINGER TIMOTHY A holds 656.51 thousand shares, Brunn Carsten has 323.53 thousand shares and Davis Blaine has 121.22 thousand shares.

Cartesian Therapeutics, Inc. generated EPS of $nan over the past year. Five-year average earnings growth is 34.24%. Wall Street analysts project EPS growth of 5.88% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $44.00 to $16.00. The high target offers 464.83% upside. The low target suggests 105.39% downside. The mean target is $36.54. This offers 369.06% upside. Cartesian Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended April 30, 2026, missed forecasts by 64.04%. The prior quarter beat by 68.29%. Over the last six quarters, Apple has recorded several small beats. These include -24.36% in March 20, 2025.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) closed at $7.79 USD, losing -$0.09 (-1.14%) from the previous close of $7.88. The stock is currently mid-range between its 52-week high and low $5.60 and $14.56. With a market capitalization of about $228.88 million, Cartesian Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.46). Key stats such as the average daily volume over the past year has been around 281.98 thousand shares, volume is running light vs its 52-week average. Headquartered in Frederick, MD, Cartesian Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carsten Brunn, the company employs approximately 75 people and listed since June 22, 2016. Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.

Cartesian Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.61. This means the shares are trading above this model’s fair value.

Cartesian Therapeutics, Inc. trades at a P/E ratio of -1.38, slightly below the S&P 500 average, with a price-to-sales ratio of 132.26 and a price-to-book ratio of -1.45 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.03, also below market averages.

Our AI price prediction model suggests that Cartesian Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.49%, with price expected at $8.14 by August 07, 2026, within a range of $6.73 to $9.64 3-Month Outlook: Projected fall of -58.92%, reaching $3.20 by October 22, 2026, with a range of $2.73 to $3.69. 1-Year Outlook: Projected gain of 79.85%, with price at $14.01 by July 23, 2027, within a range of $0.00 to $17.56.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) shares are flat 0.28% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cartesian Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.38. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $40.77, suggesting 423.36% upside. Our AI forecast model points to short-term strength (4.49% over two weeks), a medium-term fall (-58.92% over three months), and a longer-term gain (79.85% over one year), with expected trading ranges indicating moderate volatility.